Research programme: CCR1 antagonists - ChemoCentryx

Drug Profile

Research programme: CCR1 antagonists - ChemoCentryx

Alternative Names: CCX 634; CCX 9588

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 18 Apr 2016 Updated pharmacodynamics data from a preclinical trial in Breast cancer presented at American Association for Cancer Research Annual Meeting (AACR-2016) ,
  • 04 Nov 2015 Preclinical trials in Cancer in USA (unspecified route)
  • 04 Nov 2015 Pharmacodynamics data from a preclinical trial in Breast cancer released by ChemoCentryx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top